Both Cetuximab and the SM TKIs have been shown to have significant antitumor activity in various EGFR over-expressing cancers, and to enhance the potency of chemotherapy or radiotherapy in various pre-clinical and early phase I or II clinical studies [1,6-8]. Here, EGFR is linked to cancer.